PT818996E - Micro- e nanoesferas biodegradaveis contendo ciclosporina de libertacao controlada - Google Patents

Micro- e nanoesferas biodegradaveis contendo ciclosporina de libertacao controlada

Info

Publication number
PT818996E
PT818996E PT96909319T PT96909319T PT818996E PT 818996 E PT818996 E PT 818996E PT 96909319 T PT96909319 T PT 96909319T PT 96909319 T PT96909319 T PT 96909319T PT 818996 E PT818996 E PT 818996E
Authority
PT
Portugal
Prior art keywords
lactide
poly
cyclosporin
nanospheres
formulation
Prior art date
Application number
PT96909319T
Other languages
English (en)
Inventor
Zebunnissa Ramtoola
Original Assignee
Elan Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp Plc filed Critical Elan Corp Plc
Publication of PT818996E publication Critical patent/PT818996E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/795—Composed of biological material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/931—Medical device coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
PT96909319T 1995-04-03 1996-04-02 Micro- e nanoesferas biodegradaveis contendo ciclosporina de libertacao controlada PT818996E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE950233A IE75744B1 (en) 1995-04-03 1995-04-03 Controlled release biodegradable micro- and nanospheres containing cyclosporin

Publications (1)

Publication Number Publication Date
PT818996E true PT818996E (pt) 2003-06-30

Family

ID=11040700

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96909319T PT818996E (pt) 1995-04-03 1996-04-02 Micro- e nanoesferas biodegradaveis contendo ciclosporina de libertacao controlada

Country Status (14)

Country Link
US (1) US5641745A (pt)
EP (1) EP0818996B1 (pt)
JP (1) JP3875721B2 (pt)
AT (1) ATE232722T1 (pt)
AU (1) AU700612B2 (pt)
CA (1) CA2217462C (pt)
DE (1) DE69626278T2 (pt)
DK (1) DK0818996T3 (pt)
ES (1) ES2189868T3 (pt)
IE (1) IE75744B1 (pt)
NZ (1) NZ304975A (pt)
PT (1) PT818996E (pt)
WO (1) WO1996031202A1 (pt)
ZA (1) ZA962670B (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
ES2355186T3 (es) * 1997-09-05 2011-03-23 Maruho K.K. Preparaciones de nanocápsulas para tratar enfermedades intraarticulares.
NZ328751A (en) * 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
IL134591A0 (en) * 1997-09-25 2001-04-30 Bayer Ag Medicament formulation with a controlled release of an active agent
JP2001520170A (ja) 1997-10-16 2001-10-30 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム Ｎｆ−ａｔ３機能に関連した心肥大動物モデルと治療法
DE19821951A1 (de) * 1998-05-15 1999-11-18 Basf Ag Cyclosporin-Zubereitungen
US6905707B2 (en) * 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
US20050085498A1 (en) * 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
US20040259895A1 (en) * 1998-05-28 2004-12-23 Medical Research Institute Oral formulation of lipid soluble thiamine and lipoic acid
US6197340B1 (en) 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US6984404B1 (en) 1998-11-18 2006-01-10 University Of Florida Research Foundation, Inc. Methods for preparing coated drug particles and pharmaceutical formulations thereof
AU769429C (en) 1998-12-30 2004-10-28 Dexcel Limited Dispersible concentrate for the delivery of cyclosporin
US6253463B1 (en) 1999-04-26 2001-07-03 Niro A/S Method of spray drying
US6406745B1 (en) 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
GB2381453A (en) * 1999-08-31 2003-05-07 Bradford Particle Design Ltd Active/polymer coformulations
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US6682754B2 (en) * 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6565888B1 (en) * 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6869617B2 (en) * 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
BR0212833A (pt) 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
WO2003033526A2 (en) 2001-10-19 2003-04-24 Isotechnika Inc. Synthesis of cyclosporin analogs
AU2002333098B2 (en) * 2001-10-19 2006-03-16 Isotechnika Pharma Inc. Novel cyclosporin analog microemulsion preconcentrates
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
KR20030065831A (ko) * 2002-02-01 2003-08-09 주식회사 태평양 사이클로스포린을 함유한 지속 방출형 약학적 조성물
EP2085073A1 (en) * 2002-03-26 2009-08-05 Teva Pharmaceutical Industries Ltd. Drug microparticles
MXPA05005192A (es) 2002-11-15 2005-09-08 Idenix Cayman Ltd Nucleosidos ramificados en la posicion 2' y mutacion de flaviviridae.
US20040150061A1 (en) * 2003-01-30 2004-08-05 Hsin Chung Hsien Package structure of a photosensor
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
GB0413729D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
GB0413730D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
US20080280973A1 (en) * 2004-06-28 2008-11-13 Wender Paul A Laulimalide Analogues as Therapeutic Agents
CA2593043A1 (en) * 2005-02-03 2006-08-10 Cinvention Ag Drug delivery materials made by sol/gel technology
CN1323096C (zh) * 2005-05-26 2007-06-27 中国科学院长春应用化学研究所 生物可降解聚酯微粒及其制备方法和用途
BRPI0612071A2 (pt) * 2005-06-14 2010-10-19 Baxter Int formulações farmacêuticas para minimizar interações entre fármacos
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
JP2009516003A (ja) * 2005-11-15 2009-04-16 バクスター・インターナショナル・インコーポレイテッド リポキシゲナーゼ阻害剤の組成物
US20070298067A1 (en) * 2006-06-22 2007-12-27 Boston Scientific Scimed, Inc. Control release drug coating for medical devices
US7794495B2 (en) * 2006-07-17 2010-09-14 Advanced Cardiovascular Systems, Inc. Controlled degradation of stents
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
US9994585B2 (en) 2007-12-31 2018-06-12 Aphios Corporation Transplantation therapies
US20170065533A1 (en) * 2011-01-24 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nanoparticles for dermal and systemic delivery of drugs
US10624847B2 (en) * 2011-08-02 2020-04-21 AnPac BioMedical Science Co., Ltd. Decomposable apparatus and methods for fabricating same
CN104185420B (zh) 2011-11-30 2017-06-09 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
US9034347B2 (en) * 2011-12-19 2015-05-19 Arphios Corporation Drug delivery system and method for the treatment of neuro-degenerative disease
WO2014085494A1 (en) 2012-11-28 2014-06-05 Aphios Corporation Combination therapeutics and methods for the treatment of neurodegenerative and other diseases
CA2942078C (en) 2014-03-14 2023-03-14 The University Of North Carolina At Chapel Hill Small molecules for inhibiting male fertility
GB201522441D0 (en) * 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1311686C (en) * 1986-06-25 1992-12-22 John Weldon Shell Controlled release bioerodible drug delivery system
WO1989001772A1 (en) * 1987-09-03 1989-03-09 University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5185152A (en) * 1990-01-10 1993-02-09 Peyman Gholam A Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye
AU654483B2 (en) * 1990-04-18 1994-11-10 University Of Utah Research Foundation Crosslinked hydrogels containing azobonds
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
US5468503A (en) * 1992-08-13 1995-11-21 Teikoku Seiyaku Kabushiki Kaisha Oral pharmaceutical preparation released at infragastrointestinal tract

Also Published As

Publication number Publication date
AU700612B2 (en) 1999-01-07
JP3875721B2 (ja) 2007-01-31
IE75744B1 (en) 1997-09-24
EP0818996A1 (en) 1998-01-21
ZA962670B (en) 1996-10-09
ES2189868T3 (es) 2003-07-16
US5641745A (en) 1997-06-24
EP0818996B1 (en) 2003-02-19
WO1996031202A1 (en) 1996-10-10
JPH11503147A (ja) 1999-03-23
DE69626278D1 (de) 2003-03-27
NZ304975A (en) 1998-09-24
DK0818996T3 (da) 2003-06-10
DE69626278T2 (de) 2003-07-24
ATE232722T1 (de) 2003-03-15
CA2217462A1 (en) 1996-10-10
IE950233A1 (en) 1996-10-16
AU5286696A (en) 1996-10-23
CA2217462C (en) 2010-08-03

Similar Documents

Publication Publication Date Title
PT818996E (pt) Micro- e nanoesferas biodegradaveis contendo ciclosporina de libertacao controlada
AU2001255509B2 (en) Taste masking coating composition
BR9810124A (pt) Um itraconazol exibindo solibilidade incrementada, o método de preparação do mesmo e a composição farmacêutica para administração oral contendo o mesmo
MX9804008A (es) Formulaciones farmaceuticas.
BR0008059A (pt) Composições de valdecoxib
CY1105908T1 (el) Στοματικως αποσαθρουμενα δισκια που πepιλαμβανουν βενζιμιδαζολιο
WO1998009597A3 (en) Cushioning beads and tablet comprising the same capable of forming a suspension
HUP0003323A2 (hu) Vorikonazolt tartalmazó gyógyászati készítmények
CA2285266A1 (en) Extended release formulations of erythromycin derivatives
IL111647A (en) Pharmaceutical compositions comprising microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles and their preparation
GEP20032912B (en) Enteric Coated Pharmaceutical Tablets and Method of Manufacturing
EP1120109A3 (en) Rapidly disintegrating and fast dissolving solid dosage form
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
BR9908438A (pt) Tabletes de desintegração rápida
BR0010485A (pt) Formulações de derivados de eritromicina de liberação prolongada
WO1997013502A3 (en) Prolonged release of gm-csf
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
EP1074263A3 (en) Pharmaceutical compositions of macrolides or cyclosporine with a polyethoylate saturated hydroxy-fatty acid
NZ510563A (en) Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same
WO2000021525A3 (en) Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
CA2219777A1 (en) Nanoparticles for oral administration of pharmaceutical agents of low solubility
ATE253354T1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
HUP9801052A2 (hu) Orális ciklosporin készítmények
Trivedi et al. Colon targeted delivery system (CODESTM): propitious approach in targeting colon
DE69907479D1 (de) Piroxicam enthaltende gastrointestinale Zubereitung aus merheren Einheiten bestehend